Company news
Alzecure Pharma Ab (OMXSTO:ALZCUR) news
Alzecure Pharma Ab news releases on 6ix. Latest, Sep 18, 2026: AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell…
Press releases & updates
AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements
September 18, 2026
AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15
September 8, 2026
AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly
August 18, 2026
AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell
August 12, 2026
AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell
August 3, 2026
AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project
July 1, 2026
Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026
June 29, 2026
AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project
June 9, 2026
AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document
June 5, 2026
Notice To Annual General Meeting in AlzeCure Pharma AB
May 26, 2026
AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million
April 24, 2026
Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856
April 20, 2026
AlzeCure Pharma Publishes its Annual Report for 2025
April 8, 2026
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14
April 7, 2026
AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9
April 1, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD
March 19, 2026
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11
March 4, 2026
AlzeCure Publishes its Year-End Report for January - December 2025
February 26, 2026
Pain Project ACD440 Granted Orphan Drug Status in the EU
February 24, 2026
AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026
February 3, 2026
AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam
February 2, 2026
AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease
December 3, 2025
AlzeCure Publishes its Interim Report for January - September 2025
November 11, 2025
AlzeCure Pharma to Present at Redeye Neurology Day on October 15
October 7, 2025
Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025
September 8, 2025
Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference
September 4, 2025
AlzeCure Publishes its Interim Report for January - June 2025
August 26, 2025
AlzeCure Appoints Cecilia Wadell as New Head of Development
August 20, 2025
AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs
August 19, 2025
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
August 5, 2025
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
July 29, 2025
AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option
July 24, 2025
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results
July 24, 2025
AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference
July 21, 2025
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
July 16, 2025
AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA
July 15, 2025
The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares
July 2, 2025
AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue
June 17, 2025
Notice To Extraordinary General Meeting In Alzecure Pharma AB
June 16, 2025
AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million
June 16, 2025
AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease
June 12, 2025
AlzeCure Pharma to present at Redeye Investor Forum on June 11
June 4, 2025
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10
June 3, 2025
Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025
May 14, 2025
AlzeCure Publishes its Interim Report for January - March 2025
May 5, 2025